Catalog Number：VQ3055H
Human PD-L1 VeriQuant Immunoassay Kit
Copy Product Infomation
Size：
96 T
Price：
Inquiry
Manual
MSDS
User Guide(a) Two monoclonal antibodies against distinct epitopes are conjugated with oligo probes, then form a sandwich complex with the antigen.
(b) Following antigen recognition by the paired antibodies, the conjugated oligonucleotides are spatially proximate, and generate an amplifiable dsDNA template under the enzymatic action.
(c) qPCR amplification is then performed. CT values correlate inversely with protein concentration, and sample target concentrations are calculated via standard curve.
Color-coded reagents components for easy identification
Kit outer packaging and components packaging
Product Operation Video
Product Details
| Product Name | Human PD-L1 VeriQuant Immunoassay Kit | Species | Human |
| Gene Alias | CD274 / B7H1 / PDCD1L1 / PDCD1LG1 / PDL1 | Gene ID | 29126 |
| Uniprot ID | Q9NZQ7 | Protein Alias | Human PD-L1 |
| Detection Method | Proximity-based Immunoassay | Sensitivity | 0.3231pg/mL |
| Assay Instrument | qPCR Instruments | Detection Range | 1.28-20000pg/mL |
| Sample Type | Serum, Plasma, Tissue homogenates, Cell lysates, Cell culture supernates and Other biological fluids；Sample Volume=1~5μL | ||
| Total Assay Time | 2 H | Manual Handling Time | 20 min |
| Shipping Temperature | Ultra-low temperature phase-change materials | Storage Temperature | -20°C |
| No Washing Step | Yes | Tag or Dye | FAM™ |
| Kit Info | N/A | ||
| Target Info | CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. | ||